Development of Liposomal Systems of Finasteride for Topical Applications: Design, Characterization, and In Vitro Evaluation

REFERENCES

• Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J. Steroid Biochem. Mol. Biol. 1990; 37: 375–378
   PubMed Web of Science ®Google Scholar
• Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., Issacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin. Cancer Res. 2006; 12: 4072–4079
   PubMed Web of Science ®Google Scholar
• Canby-Hagino E.D., Brand T.C., Hernandez J., Thompson I.M. Chemoprevention of prostate cancer with finasteride. Expert Opin. Pharmacother. 2006; 7: 899–905
   PubMed Web of Science ®Google Scholar
• Teillac P., Abrahamsson P.A. The role of Finasteride in the management of BPH and in the prevention of prostate cancer. Eur. Urol. Suppl. 2006; 5: 627
   Web of Science ®Google Scholar
• Thompson M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Lieber M.M., Cespedes R.D., Atkins J.N., Lippman S.M., Carlin S.M, Ryan A., Szczepanek C.M., Crowley J.J., Coltman C.A., Jr. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003; 349: 215–224
   PubMed Web of Science ®Google Scholar
• Geller J. Five-year follows up of patients with benign prostatic hyperplasia treated with finasteride. Eur. Urol. 1995; 27: 267–273
   PubMed Web of Science ®Google Scholar
• Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., Andriole G.L., Geller J., Bracken B.R., Tenover J.S. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 1992; 327: 1185–1191
   PubMed Web of Science ®Google Scholar
• Chen W., Zouboulis C.C., Orfanos C.E. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177–184
   PubMed Web of Science ®Google Scholar
• Van Neste D. Natural scalp hair regression in preclinical stages of male androgenetic alopecia and its reversal by finasteride. Skin Pharmacol. Physiol. 2006; 19: 168–176
   PubMed Web of Science ®Google Scholar
• Moghetti M., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., Bellotti G., Muggeo M. Clinical and hormonal effects of 5 alpha-reducatse inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 1994; 79: 115–1121
   Web of Science ®Google Scholar
• Meidan V.M., Touitou E. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Drugs 2001; 61: 53–69
   PubMed Web of Science ®Google Scholar
• Wong L., Morris R.S., Chang L., Spahn M.A., Stanczy F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 1995; 80: 233–238
   PubMed Web of Science ®Google Scholar
• Shapiro J., Kaufman K.D. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J. Invest. Dermatol. Symp. Proc. 2003; 8: 20–23
   PubMedGoogle Scholar
• Mellin T.N., Busch R.D., Rasmusson G.H. Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin. J. Steroid Biochem. Mol. Biol. 1993; 44: 121–131
   PubMed Web of Science ®Google Scholar
• Diani A.R., Mulholland M.J., Shull K. Hair growth effects of oral administration of finasteride, a steroid 5-alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stump tail macaque. J. Clin. Endocrinol. Metab. 1992; 74: 345–350
   PubMed Web of Science ®Google Scholar
• http://www.propecia.com/finasteride/propecia/consumer/index.jsp, Propecia® (Finasteride): Information for health care professionals. Merck & Co. Inc. Whitehouse Station, NJ 08889, USA
   Google Scholar
• Chen C., Puy L.A., Simrad J., Li X., Singh S.M., Labrie F. Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzymatic activity. J. Invest. Dermatol. 1995; 105: 678–682
   PubMed Web of Science ®Google Scholar
• Choudhry R., Hodgin M.B., Vander Kwast T.H., Brinkmann A.O., Boersma W.J. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous gland and sweat glands. J. Endocrinol. 1992; 133: 467–475
   PubMed Web of Science ®Google Scholar
• Price V.H., Menefee E., Sanchez M., Kaufman K.D. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three- and 4-year results. J. Am. Acad. Dermatol. 2006; 55: 71–74
   PubMed Web of Science ®Google Scholar
• Price V.H., Roberts J.L., Hordinsky M., Olsen E.A., Savin R., Bergfeld W., Fiedler V., Lucky A., Whiting D.A., Pappas F., Culbertson J., Kotey P., Meehan A., Waldstreicher J. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J. Am. Acad. Dermatol. 2000; 43: 768–776
   PubMed Web of Science ®Google Scholar
• Green L. Gynacomastia and breast cancer during finasteride therapy. N. Engl. J. Med. 1996; 335: 823
   PubMed Web of Science ®Google Scholar
• Steiner J.F. Clinical phamacokinetics and pharmacodynamics of finasteride. Clin. Phamacokinet. 1996; 30: 16–27
   PubMed Web of Science ®Google Scholar
• Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int. J. Pharm. 1999; 184: 1–6
   PubMed Web of Science ®Google Scholar
• Cevc G. Drug delivery across the skin. Expert. Opin. Investig. Drugs 1997; 6: 1887–1937
   PubMedGoogle Scholar
• Hadgraft J. Recent developments in topical and transdermal delivery. Eur. J. Drug. Metab. Pharmacokinet. 1996; 21: 165–173
   PubMed Web of Science ®Google Scholar
• Goyal P., Goyal K., Kumar V., Singh A., Katare O.P., Mishra D.N. Liposomal drug delivery systems—Clinical applications. Acta Pharm. 2005; 55: 1–25
   PubMedGoogle Scholar
• Schmid M.H., Korting H. C. Liposomes: A drug carrier system for topical treatment in dermatology. Crit. Rev. Ther. Drug Carrier Syst. 1994; 11: 97–118
   PubMed Web of Science ®Google Scholar
• Fahr A., Mueller R. Cyclosporin invasomes as topical drug delivery systems for the therapy of immune system related skin diseases. European Patent Application 2002; 2054: 20020208
   Google Scholar
• Yarosh D.B. Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed. 2001; 17: 203–212
   PubMed Web of Science ®Google Scholar
• Singh B., Mehta G., Kumar R., Bhatia A., Ahuja N., Katare O.P. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr. Drug Deliv. 2005; 2: 143–153
   PubMedGoogle Scholar
• Bhatia A., Kumar R., Katare O.P. Tamoxifen entrapped topical liposomes: Development, characterization and in-vitro evaluation. J. Pharm. Pharm. Sci. 2004; 7: 252–259
   PubMed Web of Science ®Google Scholar
• Agarwal R., Katare O.P., Vyas S.P. Preparation and in-vitro evaluation of liposomal/niosomal delivery systems of antipsoriatic drug dithranol. Int. J. Pharm. 2001; 228: 43–52
   PubMed Web of Science ®Google Scholar
• Bouwstra J.A., Honeywell-Nguyen P.L., Gooris G.S., Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res. 2003; 42: 1–36
   PubMed Web of Science ®Google Scholar
• Tabbakhian M., Tavakoli N., Jaafari M.R., Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes. 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int. J. Pharm. 2006; 323: 1–10
   PubMed Web of Science ®Google Scholar
• Manosroi L.K., Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int. J. Pharm. 2004; 270: 279–286
   PubMed Web of Science ®Google Scholar
• Bangham D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965; 13: 238–252
   PubMed Web of Science ®Google Scholar
• Dipali S.R., Kulkarni S.B., Betagiri G.V. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J. Pharm. Pharmacol. 1996; 48: 1112–1115
   PubMed Web of Science ®Google Scholar
• New R.R. C. Liposomes: A Practical Approach. IRL Press, Oxford 1990
   Google Scholar
• Gupta P.N., Mishra V., Rawat A., Dubey P., Mahor S., Jain S., Chatterji D. P., Vyas S.P. Non-invasive vaccine delivery in transferosomes, niosomes and liposomes: a comparative study. Int. J. Pharm. 2005; 293: 73–82
   PubMed Web of Science ®Google Scholar
• Trotta M., Peira E., Carlotti M.E., Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 2004; 270: 119–125
   PubMed Web of Science ®Google Scholar
• Manosroi A., Podjanasoonthon K., Manosroi J. Development of novel topical tranexamic acid liposome formulation. Int. J. Pharm. 2002; 235: 61–70
   PubMed Web of Science ®Google Scholar
• Heurtault B., Saulnier P., Pech B., Proust J.E., Jean-Pierre B. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003; 24: 4283–4300
   PubMed Web of Science ®Google Scholar
• Carafa M., Santucci E., Lucania G. Lidocaine-loaded non-ionic surfactant vesicles: Characterization and in vitro permeation studies. Int. J. Pharm. 2002; 231: 21–32
   PubMed Web of Science ®Google Scholar
• Valenta C., Wanka M., Heidlas J. Evaluation of a novel soya-lecithin formulation for dermal use containing ketoprofen as a model drug. J. Control. Release 2000; 63: 165–173
   PubMed Web of Science ®Google Scholar
• Ogiso T., Niinaka N., Iwaki M. Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J. Pharm. Sci. 1996; 85: 57–64
   PubMed Web of Science ®Google Scholar
• Dreher F., Walde P., Walther P., Wehrli E. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J. Control. Release 1997; 45: 131–140
   Web of Science ®Google Scholar
• Walde P., Giuliani A.M., Boicelli C.A., Luisi P.L. Phospholipid-based reverse micelles. Chem. Phys. Lipids 1990; 53: 265–288
   PubMed Web of Science ®Google Scholar
• Fahr A., Blume G., Verma S., Verma D.D. Particle size of liposomes influences dermal delivery of substances into skin. Int. J. Pharm. 2003; 258: 141–151
   PubMedGoogle Scholar
• Yu H.Y., Liao H.M. Triamcinolone permeation from different liposome formulations through rat skin in-vitro. Int. J. Pharm. 1996; 127: 1–7
   Web of Science ®Google Scholar
• Abraham W., Downing D.T. Interaction between corneocytes and stratum corneum lipid liposomes in vitro. Biochim. Biophys. Acta 1990; 1021: 119–125
   PubMed Web of Science ®Google Scholar
• du Plessis, J., Ramachandran C., Weiner N., Muller D.G. The influence of particle size of liposomes on the deposition of drug into skin. 1994; 103: 277–282
   Google Scholar
• Yarosh D.B. Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed. 2001; 17: 203–212
   PubMed Web of Science ®Google Scholar
• Gabrijelcic V., Sentjure M. Influence of hydrogels on liposome stability and on the transport of liposome entrapped substances into the skin. Int. J. Pharm. 1995; 118: 207–212
   Web of Science ®Google Scholar